Dose Escalation with Three-dimensional Conformal Radiotherapy for Prostate Cancer. Is More Dose Really Better in High-risk Patients Treated with Androgen Deprivation?

Clinical Oncology

Volumn 18, Issue 8, 2006, Pages 600-607

  Zapatero, A ^a   Rios P ^a   Marin A ^a   Minguez R ^a   Garcia Vicente F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Androgen deprivation; conformal radiotherapy; dose escalation; prostate cancer; prostate specific antigen

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 33748150858     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.06.010     Document Type: Article

References (28)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
4. Fiveash J.B., Hanks G., Roach M., et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 47 (2000) 335-342
5. Vicini F.A., Abner A., Baglan K.L., Kestin L.L., and Martinez A.A. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?. Int J Radiat Oncol Biol Phys 51 (2001) 1200-1208
6. Hanks G.E., Hanlon A.L., Epstein B., and Horwitz E.M. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
7. Zietman A.L., DeSilvio M., Slater J.D., et al. A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. (Abstract). Int J Radiat Oncol Biol Phys 60 (2004) 131
8. Kupelian P.A., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
9. Zietman A.L., Nakfoor B.M., Prince E.A., and Gerweck L.E. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 3 (1997) 31-36
10. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38 (1997) 1071-1077
11. Pollack A., Salem N., Ashoori F., et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 51 (2001) 1002-1007
12. Roach III M., Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
13. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360 (2002) 103-106
14. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
15. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
16. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
17. Hanks G.E., Pajak T.F., Porter A., et al. Radiation Therapy Oncology Group phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
18. Zapatero A., Cruz-Conde A., Mínguez R., Rodríguez F., and Pérez-Torrubia A. Control Bioquímico tras Radioterapia Externa en el Cáncer de Próstata Localizado: Resultados de una Cohorte Moderna. Actas Urol Esp 24 (2000) 10-18
19. Zapatero A., Garcia-Vicente F., Modolell I., et al. Impact of mean rectal dose on late rectal bleeding following conformal radiotherapy for prostate cancer: dose volume effect. Int J Radiat Oncol Biol Phys 59 (2004) 1343-1351
20. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 32 (1995) 567-576
21. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
22. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
23. Cox D.R. Regression models and life tables. J R Stat Soc (B) 34 (1972) 187-220
24. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. J Am Med Assoc 292 (2004) 821-827
25. Zapatero A., Valcárcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23 (2005) 6561-6568
26. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
27. Gardner B.G., Zietman A.L., Shipley W.U., Skowronski U.E., and McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167 (2002) 123-126
28. Peeters S.T.H., Heemsbergen W.D., Van Putten W.L.J., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034